Answers are grounded in this paper and cite their sources.
Exploratory trial evaluates biomarkers for melanoma outcomes, suggesting potential clinical relevance.
Background and Objectives: Systemic inflammation contributes to melanoma progression, yet the prognostic value of routinely available inflammatory ratios remains insufficiently characterized in real-world cohorts. We evaluated whether pre-treatment neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) are independently associated with sentinel lymph node (SLN) positivity, histopathologic aggressiveness, and recurrence-free survival (RFS) in primary cutaneous melanoma. Methods: In this single-center, retrospective, exploratory, observational cohort, 87 adults with histologically confirmed primary cutaneous melanoma were stratified by pre-treatment NLR using a cut-off of 3.0 into low-NLR (n = 47) and high-NLR (n = 40) groups. Outcomes included Breslow thickness, ulceration, mitotic rate, AJCC stage, SLN status, and RFS over a median follow-up of 38.4 months. Discrimination was assessed by receiver operating characteristic (ROC) analysis, time-to-event endpoints by Kaplan–Meier and Cox proportional-hazards modelling, and SLN positivity by multivariable logistic regression. Results: High-NLR patients had thicker (median 2.1 vs. 0.8 mm, p < 0.001), more frequently ulcerated (42.5% vs. 12.8%, p = 0.003), and more advanced melanomas (early stage 27.5% vs. 68.1%, p < 0.001). SLN positivity among biopsied patients was 35.5% vs. 8.7% (p = 0.027). For RFS, NLR ≥ 3.0 carried a univariable hazard ratio (HR) of 4.32 (95% CI 1.60–11.67) and remained independently prognostic after multivariable adjustment (adjusted HR 2.87, 95% CI 1.04–7.92, p = 0.042). An NLR + PLR composite outperformed Breslow thickness for predicting SLN positivity (AUC 0.829 vs. 0.702, DeLong p = 0.041). Conclusions: In this exploratory, single-center retrospective cohort, pre-treatment NLR and PLR were inexpensive, widely available biomarkers that were associated with prognostically relevant melanoma features and outcomes. These hypothesis-generating findings suggest that inflammatory ratios could complement conventional histopathologic predictors, but they were derived and tested within a single small cohort without independent validation and require confirmation in larger, prospective, multi-center studies before any clinical application.
No takes yet. Share an insight, caveat, or question.
Grigore et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: